Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05068947 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects
A Phase 1 study, sponsored by Graviton Bioscience Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05068947 is a Phase 1 study that has completed, run by Graviton Bioscience Corporation. The registered enrollment target is 16 participants.
The verdict
NCT05068947, a Phase 1 study, has completed, sponsored by Graviton Bioscience Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study.
Interventions
- DRUG Placebo
- DRUG GV101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05068947
The ClinicalTrials.gov registry entry for NCT05068947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graviton Bioscience Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05068947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05068947 about?
NCT05068947 is a clinical study titled "Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects". This is a single center Phase 1, placebo-controlled, randomized, double blind, first-in-human (FIH), sequential single ascending dose (SAD) study.
What is the current status of trial NCT05068947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-09-10. Estimated completion is 2021-10-22.
What interventions are being tested in trial NCT05068947?
The interventions under investigation include: Placebo (DRUG), GV101 (DRUG).
Who is sponsoring clinical trial NCT05068947?
This trial is sponsored by Graviton Bioscience Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.